Sign In
Buy TRVN
$0.0010
+0 (+0%)
At Close: Jun 03, 2026
Trevena Awarded OLINVYK Agreement with Premier, Inc.
07:00am, Monday, 04'th Dec 2023
CHESTERBROOK, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with cent
Trevena Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries
07:00am, Thursday, 30'th Nov 2023
Results from investigator-initiated RELIEVE study will be presented at the 2024 American Burn Association (ABA) Annual Meeting in Chicago from April 9th-12th Results from investigator-initiated RELIEV
Trevena, Inc. (TRVN) Q3 2023 Earnings Call Transcript
09:21am, Tuesday, 14'th Nov 2023
Trevena, Inc. (TRVN) Q3 2023 Earnings Call Transcript
Trevena Reports Third Quarter 2023 Results and Provides Business Update
07:00am, Tuesday, 14'th Nov 2023
Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS target engagement
Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023
07:00am, Thursday, 09'th Nov 2023
CHESTERBROOK, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with cen
Trevena Reports Favorable TRV045 Topline Safety and Tolerability Data from Proof-of-Concept Studies
07:00am, Monday, 16'th Oct 2023
TRV045 was well tolerated with results generally consistent with prior first-in-human study No drug-related adverse events and no serious adverse events reported No drug-related lymphopenia, bradycard
Continuous respiratory monitoring data for ~200 complex surgical patients treated with IV OLINVYK at Cleveland Clinic and Wake Forest Baptist Health in the VOLITION study provides insights into respir
Trevena Announces Receipt of $15 Million Non-Dilutive Tranche and Provides General Business Update
07:01am, Wednesday, 06'th Sep 2023
$15 million tranche from ex-US royalty-based financing, triggered by first commercial sale of OLINVYK by Jiangsu Nhwa, Trevena's partner in China
Trevena Announces Preliminary TRV045 Data from Two Proof-of-Concept Studies Evaluating S1PR Mechanism of Action and CNS Target Engagement
07:00am, Wednesday, 06'th Sep 2023
TRV045 Demonstrated Statistically Significant Analgesic Effect in Capsaicin-induced Model of Neuropathic Pain in Target Engagement POC Study
Trevena Reports Second Quarter 2023 Results and Provides Business Update
07:00am, Monday, 14'th Aug 2023
Company announces database lock for TRV045 proof-of-concept TMS study evaluating potential for use in epilepsy; topline data expected 3Q 2023
Trevena, Inc. Appoints Mark Corrigan, M.D. to Board of Directors
07:00am, Thursday, 20'th Jul 2023
CHESTERBROOK, Pa. , July 20, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with ce
Trevena Announces New Topline OLINVYK Data Highlighting Reduced Cost per Admission from ARTEMIS Real-World Outcomes Study
07:00am, Monday, 26'th Jun 2023
OLINVYK-treated patients (n=201) had a statistically significant ~$8,750 (19%) lower cost per admission and ~1.4 day (20%) reduced average length of hospital stay, compared to matched patients treated
Go Beyond Bargain Hunting; Buy 5 Stocks With Rising P/E
09:10am, Monday, 05'th Jun 2023
Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include OpGen (OPGN), The RealReal (REAL), Trevena (TRVN), ChargePoint (CHPT) and Caterpillar (CAT).
5 Hot Penny Stocks To Watch With Big News This Week
11:16am, Wednesday, 31'st May 2023
Whether you're trading penny stocks or higher-priced company shares, everyone wants to gain an edge. In the stock market today, there are plenty of catalysts to consider.
Trevena Announces Receipt of Milestone Payment From Partner in China Jiangsu Nhwa Pharmaceutical
07:00am, Wednesday, 31'st May 2023
$3 million milestone payment for Chinese approval of OLINVYK® (oliceridine) injection The Company also eligible to receive $15 million non-dilutive financing tranche from R-Bridge upon first commerci
